Exploration of the Associations of lncRNA Expression Patterns with Tumor Mutation Burden and Prognosis in Colon Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. Br J Cancer. 2018;119(7):785–792. doi:10.1038/s41416-018-0264-x
   PubMed Web of Science ®Google Scholar
• Tjandra JJ, Chan MKY. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50(11):1783–1799. doi:10.1007/s10350-007-9030-5
   PubMed Web of Science ®Google Scholar
• Kamal Y, Cheng C, Frost HR, Amos CI. Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma. Oncoimmunology. 2019;8(1):e1500106. doi:10.1080/2162402X.2018.1500106
   PubMed Web of Science ®Google Scholar
• Hoos A. Development of immuno-oncology drugs – from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235–247. doi:10.1038/nrd.2015.35
   PubMed Web of Science ®Google Scholar
• Kaufmann SHE. Immunology’s coming of age. Front Immunol. 2019;10:684. doi:10.3389/fimmu.2019.00684
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–856. doi:10.1158/1535-7163.MCT-14-0983
   PubMed Web of Science ®Google Scholar
• Zito Marino F, Ascierto PA, Rossi G, et al. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? Expert Opin Biol Ther. 2017;17(6):735–746. doi:10.1080/14712598.2017.1309387
   PubMed Web of Science ®Google Scholar
• Braun DA, Burke KP, Van Allen EM. Genomic approaches to understanding response and resistance to immunotherapy. Clin Cancer Res. 2016;22(23):5642–5650. doi:10.1158/1078-0432.CCR-16-0066
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–e551. doi:10.1016/S1470-2045(16)30406-5
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee C-H, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206. doi:10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi:10.1093/annonc/mdy495
   PubMed Web of Science ®Google Scholar
• Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096–1103. doi:10.1093/annonc/mdz134
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186/s13073-017-0424-2
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386
   PubMed Web of Science ®Google Scholar
• Garofalo A, Sholl L, Reardon B, et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016;8(1):79. doi:10.1186/s13073-016-0333-9
   PubMedGoogle Scholar
• Heeke S, Hofman P. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? Transl Lung Cancer Res. 2018;7(6):631–638. doi:10.21037/tlcr.2018.08.04
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science (New York, NY). 2015;348(6230):69–74. doi:10.1126/science.aaa4971
   Google Scholar
• Anderson DM, Anderson KM, Chang C-L, et al. A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell. 2015;160(4):595–606. doi:10.1016/j.cell.2015.01.009
   PubMed Web of Science ®Google Scholar
• Nelson BR, Makarewich CA, Anderson DM, et al. A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. Science (New York, NY). 2016;351(6270):271–275. doi:10.1126/science.aad4076
   Google Scholar
• Wilusz JE. Long noncoding RNAs: re-writing dogmas of RNA processing and stability. Biochim Biophys Acta. 2016;1859(1):128–138. doi:10.1016/j.bbagrm.2015.06.003
   PubMed Web of Science ®Google Scholar
• Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21. doi:10.1038/nrg3606
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981. doi:10.1158/0008-5472.CAN-16-2634
   PubMed Web of Science ®Google Scholar
• Vishnubalaji R, Shaath H, Elango R, Alajez NM. Noncoding RNAs as potential mediators of resistance to cancer immunotherapy. Semin Cancer Biol. 2019.
   Web of Science ®Google Scholar
• Hu Q, Ye Y, Chan L-C, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019;20(7):835–851. doi:10.1038/s41590-019-0400-7
   PubMed Web of Science ®Google Scholar
• Huang D, Chen J, Yang L, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018;19(10):1112–1125. doi:10.1038/s41590-018-0207-y
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhu Y, Xie Y, Ma X. The role of long non-coding RNAs in immunotherapy resistance. Front Oncol. 2019;9:1292. doi:10.3389/fonc.2019.01292
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940. doi:10.1172/JCI91190
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61. doi:10.1016/j.cell.2014.12.033
   PubMed Web of Science ®Google Scholar
• Li Y, Jiang T, Zhou W, et al. Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nat Commun. 2020;11(1):1000. doi:10.1038/s41467-020-14802-2
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Lech G, Słotwiński R, Słodkowski M, Krasnodębski IW. Colorectal cancer tumour markers and biomarkers: recent therapeutic advances. World j Gastroenterol. 2016;22(5):1745–1755. doi:10.3748/wjg.v22.i5.1745
   PubMed Web of Science ®Google Scholar
• Koeppel F, Blanchard S, Jovelet C, et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017;12(11):e0188174. doi:10.1371/journal.pone.0188174
   PubMed Web of Science ®Google Scholar
• Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J clin oncol. 2018;36(7):633–641. doi:10.1200/JCO.2017.75.3384
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, NY). 2015;348(6230):124–128. doi:10.1126/science.aaa1348
   Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–1986. doi:10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441–1448. doi:10.1038/s41591-018-0134-3
   PubMed Web of Science ®Google Scholar
• Fenizia F, Pasquale R, Roma C, Bergantino F, Iannaccone A, Normanno N. Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. Transl Lung Cancer Res. 2018;7(6):668–677. doi:10.21037/tlcr.2018.09.23
   PubMed Web of Science ®Google Scholar
• Cortez MA, Anfossi S, Ramapriyan R, et al. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019;58(4):244–253. doi:10.1002/gcc.22725
   PubMed Web of Science ®Google Scholar
• Boeri M, Milione M, Proto C, et al. Circulating miRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a Prospective Study. Clin Cancer Res. 2019;25(7):2166–2173. doi:10.1158/1078-0432.CCR-18-1981
   PubMed Web of Science ®Google Scholar
• Sun J, Zhang Z, Bao S, et al. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer. 2020;8(1):e000110. doi:10.1136/jitc-2019-000110
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhang Z, Bao S, et al. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform. 2020.
   Web of Science ®Google Scholar
• Berg KCG, Eide PW, Eilertsen IA, et al. Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. Mol Cancer. 2017;16(1):116. doi:10.1186/s12943-017-0691-y
   PubMedGoogle Scholar
• Zhao Z, Li W, Zhang X, Ge M, Song C. Correlation between TMB and MSI in patients with solid tumors. J Clin Oncol. 2020;38:e15169–e15169. doi:10.1200/JCO.2020.38.15_suppl.e15169
   Google Scholar
• Song J, Xu Q, Zhang H, et al. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma. J Cell Biochem. 2018;119(6):4559–4569. doi:10.1002/jcb.26598
   PubMed Web of Science ®Google Scholar
• Cai C, Yang L, Tang Y, et al. Prediction of overall survival in gastric cancer using a nine-lncRNA. DNA Cell Biol. 2019;38(9):1005–1012. doi:10.1089/dna.2019.4832
   PubMed Web of Science ®Google Scholar
• Wu B, Wang K, Fei J, et al. Novel three‑lncRNA signature predicts survival in patients with pancreatic cancer. Oncol Rep. 2018;40(6):3427–3437. doi:10.3892/or.2018.6761
   PubMed Web of Science ®Google Scholar